Suzuki Jun, Broeyer Freerk, Cohen Adam, Takebe Masato, Burggraaf Jacobus, Mizushima Yutaka
R&D Division, LTT Bio-Pharma Co, Ltd, Tokyo 105-6201, Japan.
J Clin Pharmacol. 2008 Feb;48(2):184-92. doi: 10.1177/0091270007309705. Epub 2007 Dec 18.
To study the pharmacokinetics of single increasing intravenous doses (40-160 mg) and repeated doses (80 mg for 7 days) of lecithinized superoxide dismutase (PC-SOD) in Japanese volunteers and to compare the pharmacokinetics of PC-SOD between Caucasians and Japanese. The Japanese study consisted of 2 parts: a single-dose, open-label, dose-escalation part and a multiple-dose, single-blind, placebo-controlled part. The pharmacokinetics of PC-SOD were determined using noncompartmental and compartmental methods. Pharmacokinetic data from a study with PC-SOD in Caucasians were reanalyzed using the same methodology. The mean (SD) terminal half-life of PC-SOD in Japanese subjects was 25 (4) hours for the 40-mg and 80-mg doses and 31 (15) hours for the 160-mg dose. There was nonlinearity between dose-normalized C(max) and clearance (P values .002 and .022). After multiple dosing, steady state was reached after 5 days. The observed accumulation ratio was 2.6 (0.5). The pharmacokinetics of the single 80-mg dose were similar for Japanese and Caucasians. The pharmacokinetics of PC-SOD was shown to be nonlinear with dose, which may be attributable to a saturable clearing mechanism. The relatively long half-life of PC-SOD (>24 hours) suggests that it is worthwhile to study the compound as a protective agent in clinical conditions with free radical overload.
研究在日本志愿者中单次递增静脉注射剂量(40 - 160毫克)和重复剂量(80毫克,持续7天)的卵磷脂化超氧化物歧化酶(PC - SOD)的药代动力学,并比较白种人和日本人之间PC - SOD的药代动力学。日本的研究包括两部分:单剂量、开放标签、剂量递增部分和多剂量、单盲、安慰剂对照部分。使用非房室和房室方法测定PC - SOD的药代动力学。使用相同方法重新分析了一项在白种人中进行的PC - SOD研究的药代动力学数据。在日本受试者中,40毫克和80毫克剂量的PC - SOD平均(标准差)终末半衰期为25(4)小时,160毫克剂量为31(15)小时。剂量标准化的C(max)与清除率之间存在非线性关系(P值分别为.002和.022)。多次给药后,5天后达到稳态。观察到的蓄积比为2.6(0.5)。单次80毫克剂量的药代动力学在日本人和白种人中相似。PC - SOD的药代动力学显示出与剂量的非线性关系,这可能归因于一种可饱和的清除机制。PC - SOD相对较长的半衰期(>24小时)表明,在自由基过载的临床情况下将该化合物作为一种保护剂进行研究是值得的。